中文版     ENGLISH

澤爾瑞英.png

scan it,Follow us

News classification

Product

Contact

Hangzhou ZeErRui Chemical Co., Ltd

Add:No 317,Jingling Road,Guali Town,Xiaoshan District,Hangzhou,Zhejiang

Tel:+86-571-57153510

Mobile:+86-15267108660(Mrs. Pan)

Fax:+86-571-57153510

Zip Code:311241

E-mail:sales@zeerrui.com

Web:www.picuket.com 


Limaprost

Your current position: Home >> News >> Technical knowledge

Limaprost

Release date:2017-11-03 Author: Click:

Limaprost (as Limaprost alfadex; CAS number 88852-12-4) is an oral prostaglandin E1 analog. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostaglandins have a wide variety of actions, including, but not limited to muscular constriction and mediation of inflammation. Limaprost alfadex has been shown to improve peripheral circulatory failure with a vasodilator action and an antithrombotic effect. It also improves poor blood flow in the nerve tissue in cervical spondylosis and normalizes nerve function. Limaprost alfadex was discovered from collaborative research between Ono Pharmaceutical (Ono) and Dainippon Sumitomo Pharma (DSP). It was approved for the treatment of ischemic symptoms such as skin ulcer, pain and coldness accompanying thromboangiitis obliterans in 1988; and for the treatment of subjective symptoms such as pain and numbness in the lower leg and walking disability associated with acquired lumbar spinal canal stenosis as an additional indication in 2001. The drug has been sold under the trade name of Opalmon? Tablets by Ono and Prorenal? Tablets by DSP. In 2011, Ono and DSP initiated Phase II clinical trials in Japan for the treatment of carpal tunnel syndrome. In 2013, these trials were discontinued because the study failed to demonstrate efficacy. Ono and DSP also discontinued the development of limaprost alfadex for the additional indication of cervical spondylosis in 2008 due to the failure to demonstrate the anticipated efficacy in a Phase II study in patients with the disease. However, it was verified by Seoul National University Hospital in November of 2014 that the study on the efficacy of oral limaprost alfadex after surgery for cervical myelopathy was still ongoing.

Related tags:supplier,manufacture,factory,74397-12-9,Limaprost

Last one:農藥原料及中間體
Next article:None

Recent browsing:

Service
share
Welcome to our message
Please enter the message content, we will contact you as soon as possible。
Full name
Full name
Telephone
Telephone
mailbox
mailbox
address
address
ku游娱乐备用网站